|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2007-10-19
|
|
pubmed:abstractText |
To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of lexatumumab (HGS-ETR2), a fully human agonistic monoclonal antibody which targets and activates the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) in patients with advanced solid malignancies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AttardGerhardtG,
pubmed-author:BarrettMaryM,
pubmed-author:CalvertHilaryH,
pubmed-author:CoreyAlfredA,
pubmed-author:FoxNorma LynnNL,
pubmed-author:HalpernWendyW,
pubmed-author:JudsonIanI,
pubmed-author:KayeStanS,
pubmed-author:LiLouiseL,
pubmed-author:PaceySimonS,
pubmed-author:PerrettRebeccaR,
pubmed-author:PlummerRuthR,
pubmed-author:RazakAlbiruniA,
pubmed-author:de BonoJohannJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6187-94
|
|
pubmed:meshHeading |
pubmed-meshheading:17947486-Adult,
pubmed-meshheading:17947486-Aged,
pubmed-meshheading:17947486-Antibodies, Monoclonal,
pubmed-meshheading:17947486-Area Under Curve,
pubmed-meshheading:17947486-Drug Administration Schedule,
pubmed-meshheading:17947486-Female,
pubmed-meshheading:17947486-Humans,
pubmed-meshheading:17947486-Immunohistochemistry,
pubmed-meshheading:17947486-Male,
pubmed-meshheading:17947486-Maximum Tolerated Dose,
pubmed-meshheading:17947486-Middle Aged,
pubmed-meshheading:17947486-Neoplasms,
pubmed-meshheading:17947486-Receptors, TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:17947486-Treatment Outcome,
pubmed-meshheading:17947486-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
|
|
pubmed:affiliation |
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom. Ruth.Plummer@newcastle.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
